The stock of Patheon NV (NYSE:PTHN) is a huge mover today! The stock decreased 2.77% or $0.82 during the last trading session, hitting $28.81. About 221,987 shares traded hands. Patheon NV (NYSE:PTHN) has risen 6.00% since September 4, 2016 and is uptrending. It has underperformed by 6.22% the S&P500.
The move comes after 6 months negative chart setup for the $4.18B company. It was reported on Oct, 4 by Barchart.com. We have $26.79 PT which if reached, will make NYSE:PTHN worth $292.60 million less.
Patheon NV (NYSE:PTHN) Ratings Coverage
Out of 12 analysts covering Patheon (NYSE:PTHN), 12 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Patheon has been the topic of 14 analyst reports since August 15, 2016 according to StockzIntelligence Inc. Jefferies initiated the stock with “Buy” rating in Tuesday, August 16 report. The rating was initiated by UBS on Monday, August 15 with “Buy”. As per Monday, August 15, the company rating was initiated by William Blair. Raymond James initiated Patheon NV (NYSE:PTHN) rating on Monday, August 15. Raymond James has “Outperform” rating and $32.50 price target. As per Monday, August 15, the company rating was initiated by PiperJaffray. The firm has “Overweight” rating by JP Morgan given on Monday, August 15. The company was initiated on Monday, August 15 by Piperjaffray. The firm earned “Outperform” rating on Monday, August 15 by Wells Fargo. Evercore initiated the shares of PTHN in a report on Tuesday, August 16 with “Buy” rating. Robert W. Baird initiated the shares of PTHN in a report on Monday, August 15 with “Outperform” rating.
According to Zacks Investment Research, “Patheon N.V. is a provider of pharmaceutical development and manufacturing services. Patheon N.V. is based in Amsterdam, Netherlands.”
More notable recent Patheon NV (NYSE:PTHN) news were published by: Businesswire.com which released: “Patheon N.V. Announces Pricing of Initial Public Offering” on July 21, 2016, also Marketwatch.com with their article: “Patheon started at buy at Evercore ISI” published on July 21, 2016, Businesswire.com published: “Patheon N.V. Announces Launch of Initial Public Offering” on July 11, 2016. More interesting news about Patheon NV (NYSE:PTHN) were released by: Seekingalpha.com and their article: “IPO Quiet Period Expiration: Patheon N.V.” published on August 10, 2016 as well as Businesswire.com‘s news article titled: “Patheon N.V. Announces Closing of Initial Public Offering and Full Exercise of …” with publication date: July 26, 2016.
PTHN Company Profile
Patheon NV, formerly Patheon Holdings Cooperatief U.A., is engaged in providing outsourced pharmaceutical development and manufacturing (CDMO) services. The Firm provides a range of active pharmaceutical ingredient (API) and finished drug product services to its customers, from formulation development to clinical and commercial-scale manufacturing, packaging, and lifecycle management. The Company’s services address both small molecule and large molecule biological drugs. Through the Company’s Patheon OneSource, provide its clients with solutions for both small molecule and large molecule biological pharmaceuticals across its three divisions, including development and manufacturing services for API (Drug Substance Services, or DSS), formulation development and pre-clinical and clinical drug product manufacturing (Pharmaceutical Development Services, or PDS) and commercial drug product manufacturing and packaging (Drug Product Services, or DPS).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.